Department of Epidemiology and Biostatistics, UCSF, Helen Diller Cancer Research Building, San Francisco, CA 94158, USA.
BMC Cancer. 2010 Sep 27;10:513. doi: 10.1186/1471-2407-10-513.
Mutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor prognosis among various subtypes of leukemia. The causes and timing of the mutations are not currently known. We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia patients from Northern California.
We screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs) among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth using sensitive "backtracking" methods.
We determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441 acute lymphocytic leukemias (ALLs, 2%). Among AMLs, FLT3 mutations were more common in older patients, and among ALLs, FLT3 mutations were more common in patients with high hyperdiploidy (3.7%) than those without this cytogenetic feature (1.4%). Five FLT3 ITDs, one deletion mutation, and 3 point mutations were assessed for their presence in neonatal Guthrie spots using sensitive real-time PCR techniques, and no patients were found to harbor FLT3 mutations at birth.
FLT3 mutations were not common in our population-based patient series in California, and patients who harbor FLT3 mutations most likely acquire them after they are born.
FLT3 基因突变导致酪氨酸激酶活性激活、细胞生长刺激,并使各种亚型白血病的预后较差。目前尚不清楚突变的原因和时间。我们评估了加利福尼亚北部儿童白血病患者人群系列中 FLT3 突变的流行率和起源时间。
我们筛选并对 517 例儿童白血病患者的 FLT3 突变(点突变和内部串联重复,ITD)进行测序,并使用灵敏的“回溯”方法评估这些突变是在出生前还是出生后发生的。
我们确定了 73 例急性髓系白血病(AML,12%)中有 9 例和 441 例急性淋巴细胞白血病(ALL,2%)中有 9 例存在突变。在 AML 中,FLT3 突变在老年患者中更为常见,而在 ALL 中,FLT3 突变在具有高超二倍体(3.7%)的患者中比不具有这种细胞遗传学特征(1.4%)更为常见。使用灵敏的实时 PCR 技术评估了 5 个 FLT3 ITD、1 个缺失突变和 3 个点突变在新生儿 Guthrie 斑中的存在情况,未发现患者在出生时存在 FLT3 突变。
在我们加利福尼亚的基于人群的患者系列中,FLT3 突变并不常见,并且携带 FLT3 突变的患者很可能在出生后获得这些突变。